NA as a neurotransmitter modulates drive, alertness and arousal, emotion and behaviour5, and the clinical efficacy of NAT inhibition in psychiatric diseases such as depression45, attention deficit/hyperactivity disorder11 as well as in MS-related depression and fatigue46 further supports an involvement of the noradrenergic system in the pathophysiology of these entities. The gene discussed is BRD2; the disease is myeloid sarcoma.